Basile Pache1,2, Vincent Balaya1,2,3, Jérôme Mathis4,5, Martin Hübner2,6, Roland Sahli7, Mathias Cavassini2,8, Christine Sempoux2,9, Patrice Mathevet1,2, Martine Jacot-Guillarmod1,2. 1. Gynecology Department, Department Women-Mother-Child, Lausanne University Hospital (CHUV), Lausanne, Switzerland. 2. University of Lausanne, Lausanne, Switzerland. 3. Department of Gynecology and Obstetrics, Foch Hospital, Suresnes, France. 4. Gynecology and Obstetrics Department, Biel Hospital Center, Biel, Switzerland. 5. Department of Obstetrics and Gynecology, University Hospital of Berne and University of Berne, Berne, Switzerland. 6. Department of Visceral Surgery, Lausanne University Hospital (CHUV), Lausanne, Switzerland. 7. Formerly at the Institute of Microbiology, Lausanne University Hospital (CHUV), Lausanne, Switzerland. 8. Division of Infectious Diseases, Lausanne University Hospital, Lausanne, Switzerland. 9. Institute of Pathology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Abstract
BACKGROUND: Human Papillomaviruses (HPV) are highly prevalent in the sexually active populations, with a significant burden in terms of health and psychological cost in all class ages. High-risk (HR) HPV genotypes are associated with anogenital dysplasia and cancers, and anal HPV-induced cancer is increasingly observed in women. The interactions of HPV genotype's between the anus and the cervix, and the subsequent occurrence of dysplasia remains unclear. This clinical study set out to test the hypothesis that risk factors for anal HR-HPV and dysplasia may differ in women with or without cervical dysplasia or in HIV-positive women. METHODS: Cervical and anal HPV genotypes and cytology testing will be performed prospectively in a cohort of women recruited in a tertiary university hospital in Switzerland. Women will be allocated to three groups: 1) normal previous cervical smear; 2) high-grade cervical dysplasia (H-SIL) at previous cervical smear; 3) HIV+, independently of previous cervical smear result. General inclusion criteria comprised the followings: Female-Age > = 18 years; Satisfactory understanding of French; No objection to HIV testing. Specific inclusion criteria are: Group 1, no past or current gynecological dysplasia and HIV negative; Group 2, Gynecological dysplasia (H-SIL) or carcinoma in situ demonstrated by histology (vulvar, vaginal or cervical) and HIV negative; Group 3: HIV-positive (regardless of viremia or CD4 count) with or without gynecological dysplasia. General exclusion criteria are: Pregnancy; History of anal dysplasia/cancer; Status after pelvic radiotherapy; Absence of anus and anal canal. Estimated prevalences of anal dysplasia are: in group 1, 1% (0-2%); in group 2, 15% (5-27%), and in group 3, 30% (19-45%). With a 10% margin error, a sample size of 120 women per group is required to reach 90% power for detecting statistical significance (unilateral α error of 5%). DISCUSSION: The primary endpoint is the prevalence of anal and cervical dysplasia, and description of the respective HPV genotypes in each group. The results of this study could improve the standard of screening of cervical and anal dysplasia in women through evidence of concomitant presence of HPV's and/or dysplasia in anus or cervix to support vaccination for instance. Beginning of recruitment started in September 2016. Results should be presented in end of 2022. Preliminary analysis for first 100 patients reveals that the mean age of the population is 39.6 (± 10.9) years with mean age of first sexual intercourse of 18.5 (± 3.9) years. In this cohort, 12% are vaccinated and 38% having had anal intercourse. Overall, 43% of the studied population had cervical HR-HPV in the studied population, and 53% had normal cytology. Anal LR HPV and HR HP were found in 27.6% and 38.4% of all patients respectively. Eighty percent had normal anal cytology. Groups 1,2 and 3 had a significant difference in terms of age, gestity, parity, age of first sexual intercourse, systematic use of condom, number of cervical LR HPV and HR HPV and abnormal cervical cytologies. TRIAL REGISTRATION: The study was approved by the institutional review board-CER-VD#2015-00200-on the 29th of June 2016 and is registered on the Swiss National Clinical Trials Portal (SNCTP), SNCTP000002567, Registered 29 June 2016, https://www.kofam.ch/en/snctp-portal/study/40742/.
BACKGROUND: Human Papillomaviruses (HPV) are highly prevalent in the sexually active populations, with a significant burden in terms of health and psychological cost in all class ages. High-risk (HR) HPV genotypes are associated with anogenital dysplasia and cancers, and anal HPV-induced cancer is increasingly observed in women. The interactions of HPV genotype's between the anus and the cervix, and the subsequent occurrence of dysplasia remains unclear. This clinical study set out to test the hypothesis that risk factors for anal HR-HPV and dysplasia may differ in women with or without cervical dysplasia or in HIV-positive women. METHODS: Cervical and anal HPV genotypes and cytology testing will be performed prospectively in a cohort of women recruited in a tertiary university hospital in Switzerland. Women will be allocated to three groups: 1) normal previous cervical smear; 2) high-grade cervical dysplasia (H-SIL) at previous cervical smear; 3) HIV+, independently of previous cervical smear result. General inclusion criteria comprised the followings: Female-Age > = 18 years; Satisfactory understanding of French; No objection to HIV testing. Specific inclusion criteria are: Group 1, no past or current gynecological dysplasia and HIV negative; Group 2, Gynecological dysplasia (H-SIL) or carcinoma in situ demonstrated by histology (vulvar, vaginal or cervical) and HIV negative; Group 3: HIV-positive (regardless of viremia or CD4 count) with or without gynecological dysplasia. General exclusion criteria are: Pregnancy; History of anal dysplasia/cancer; Status after pelvic radiotherapy; Absence of anus and anal canal. Estimated prevalences of anal dysplasia are: in group 1, 1% (0-2%); in group 2, 15% (5-27%), and in group 3, 30% (19-45%). With a 10% margin error, a sample size of 120 women per group is required to reach 90% power for detecting statistical significance (unilateral α error of 5%). DISCUSSION: The primary endpoint is the prevalence of anal and cervical dysplasia, and description of the respective HPV genotypes in each group. The results of this study could improve the standard of screening of cervical and anal dysplasia in women through evidence of concomitant presence of HPV's and/or dysplasia in anus or cervix to support vaccination for instance. Beginning of recruitment started in September 2016. Results should be presented in end of 2022. Preliminary analysis for first 100 patients reveals that the mean age of the population is 39.6 (± 10.9) years with mean age of first sexual intercourse of 18.5 (± 3.9) years. In this cohort, 12% are vaccinated and 38% having had anal intercourse. Overall, 43% of the studied population had cervical HR-HPV in the studied population, and 53% had normal cytology. Anal LR HPV and HR HP were found in 27.6% and 38.4% of all patients respectively. Eighty percent had normal anal cytology. Groups 1,2 and 3 had a significant difference in terms of age, gestity, parity, age of first sexual intercourse, systematic use of condom, number of cervical LR HPV and HR HPV and abnormal cervical cytologies. TRIAL REGISTRATION: The study was approved by the institutional review board-CER-VD#2015-00200-on the 29th of June 2016 and is registered on the Swiss National Clinical Trials Portal (SNCTP), SNCTP000002567, Registered 29 June 2016, https://www.kofam.ch/en/snctp-portal/study/40742/.
Authors: Scott R Steele; Madhulika G Varma; Genevieve B Melton; Howard M Ross; Janice F Rafferty; W Donald Buie Journal: Dis Colon Rectum Date: 2012-07 Impact factor: 4.585
Authors: Céline Duvoisin Cordoba; Daniel Clerc; Alice Vanoni; Basile Pache; Martin Hübner; Nicolas Demartines; Dieter Hahnloser Journal: Rev Med Suisse Date: 2018-06-13
Authors: Brenda Y Hernandez; Katharine McDuffie; Xuemei Zhu; Lynne R Wilkens; Jeffrey Killeen; Bruce Kessel; Mark T Wakabayashi; Cathy C Bertram; David Easa; Lily Ning; Jamie Boyd; Christian Sunoo; Lori Kamemoto; Marc T Goodman Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-11 Impact factor: 4.254
Authors: Erna Milunka Kojic; Susan Cu-Uvin; Lois Conley; Tim Bush; Juanita Onyekwuluje; David C Swan; Elizabeth R Unger; Keith Henry; John H Hammer; Edgar T Overton; Teresa M Darragh; Joel M Palefsky; Claudia Vellozzi; Pragna Patel; John T Brooks Journal: Sex Transm Dis Date: 2011-04 Impact factor: 2.830
Authors: Alan G Nyitray; Roberto J Carvalho da Silva; Maria Luiza Baggio; Beibei Lu; Danélle Smith; Martha Abrahamsen; Mary Papenfuss; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano Journal: J Infect Dis Date: 2011-01-01 Impact factor: 5.226
Authors: Ina U Park; James W Ogilvie; Kristin E Anderson; Zhong-ze Li; Lindsay Darrah; Robert Madoff; Levi Downs Journal: Gynecol Oncol Date: 2009-06-06 Impact factor: 5.482
Authors: Hugo De Vuyst; Gary M Clifford; Maria Claudia Nascimento; Margaret M Madeleine; Silvia Franceschi Journal: Int J Cancer Date: 2009-04-01 Impact factor: 7.396
Authors: Felipe A Castro; Wim Quint; Paula Gonzalez; Hormuzd A Katki; Rolando Herrero; Leen-Jan van Doorn; Mark Schiffman; Linda Struijk; Ana Cecilia Rodriguez; Corey DelVecchio; Douglas R Lowy; Carolina Porras; Silvia Jimenez; John Schiller; Diane Solomon; Sholom Wacholder; Allan Hildesheim; Aimée R Kreimer Journal: J Infect Dis Date: 2012-07-30 Impact factor: 5.226